{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:58:28Z","timestamp":1769216308442,"version":"3.49.0"},"reference-count":126,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Onco-hematologic patients are highly susceptible to SARS-CoV-2 infection and, once infected, frequently develop COVID-19 due to the immunosuppression caused by tumor growth, chemotherapy and immunosuppressive therapy. In addition, COVID-19 has also been recognized as a further cause of HBV reactivation, since its treatment includes the administration of corticosteroids and some immunosuppressive drugs. Consequently, onco-hematologic patients should undergo SARS-CoV-2 vaccination and comply with the rules imposed by lockdowns or other forms of social distancing. Furthermore, onco-hematologic facilities should be adapted to new needs and provided with numerically adequate health personnel vaccinated against SARS-CoV-2 infection. Onco-hematologic patients, both HBsAg-positive and HBsAg-negative\/HBcAb-positive, may develop HBV reactivation, made possible by the support of the covalently closed circular DNA (cccDNA) persisting in the hepatocytic nuclei of patients with an ongoing or past HBV infection. This occurrence must be prevented by administering high genetic barrier HBV nucleo(t)side analogues before and throughout the antineoplastic treatment, and then during a long-term post-treatment follow up. The prevention of HBV reactivation during the SARS-CoV-2 pandemic is the topic of this narrative review.<\/jats:p>","DOI":"10.3390\/pathogens11050567","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T05:10:32Z","timestamp":1652332232000},"page":"567","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-7810","authenticated-orcid":false,"given":"Caterina","family":"Sagnelli","sequence":"first","affiliation":[{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania \u201cLuigi Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-4620","authenticated-orcid":false,"given":"Antonello","family":"Sica","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-3330","authenticated-orcid":false,"given":"Massimiliano","family":"Creta","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-135X","authenticated-orcid":false,"given":"Alessandra","family":"Borsetti","sequence":"additional","affiliation":[{"name":"National HIV\/AIDS Research Center, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-9239","authenticated-orcid":false,"given":"Massimo","family":"Ciccozzi","sequence":"additional","affiliation":[{"name":"Medical Statistics and Molecular Epidemiology Unit, Campus Bio-Medico University, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-8436","authenticated-orcid":false,"given":"Evangelista","family":"Sagnelli","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania \u201cLuigi Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"ref_1","first-page":"157","article-title":"WHO Declares COVID-19 a Pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s42003-021-02025-0","article-title":"SARS-CoV-2 shifting transmission dynamics and hidden reservoirs potentially limit efficacy of public health interventions in Italy","volume":"4","author":"Giovanetti","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_3","unstructured":"(2022, May 03). Coronavirus Disease (COVID-19) Pandemic. Cited Date?. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000507423","article-title":"COVID-19 Outbreak: An Overview","volume":"64","author":"Ciotti","year":"2019","journal-title":"Chemotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jmv.25748","article-title":"Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures","volume":"92","author":"Wang","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_6","first-page":"1824","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cmi.2020.12.011","article-title":"Italian Society of Infectious and Tropical Diseases. Therapeutic strategies for severe COVID-19: A position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)","volume":"27","author":"Mussini","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","article-title":"A Review of Coronavirus Disease-2019 (COVID-19)","volume":"87","author":"Singhal","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"662746","DOI":"10.3389\/fonc.2021.662746","article-title":"More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study","volume":"11","author":"Monari","year":"2021","journal-title":"Front Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sica, A., Sagnelli, C., Casale, B., Svanera, G., Creta, M., Calogero, A., Franco, R., Sagnelli, E., and Ronchi, A. (2021). How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report. Healthcare, 9.","DOI":"10.20944\/preprints202101.0249.v1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1126\/science.abb3221","article-title":"Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)","volume":"368","author":"Li","year":"2020","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jinf.2020.05.043","article-title":"Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient","volume":"81","author":"Sagnelli","year":"2020","journal-title":"J. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jmv.26197","article-title":"The impact of the SARS-CoV-2 infection, with special reference to the hematological setting","volume":"93","author":"Sica","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/jmv.26470","article-title":"Management of SARS-CoV-2 pneumonia","volume":"93","author":"Sagnelli","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/jmv.26883","article-title":"SARS-CoV-2 infection affects the lower urinary tract and male genital system: A systematic review","volume":"93","author":"Creta","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s15010-021-01706-6","article-title":"Renal involvement in COVID-19: Focus on kidney transplant sector","volume":"49","author":"Sagnelli","year":"2021","journal-title":"Infection"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.120.047430","article-title":"Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence","volume":"142","author":"Poissy","year":"2020","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1007\/s12035-021-02450-6","article-title":"Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic","volume":"58","author":"Dewanjee","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000518581","article-title":"The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline","volume":"21","author":"Pyne","year":"2021","journal-title":"Neurodegener. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Macera, M., De Angelis, G., Sagnelli, C., Coppola, N., and Vanvitelli COVID-19 Group (2020). Clinical Presentation of COVID-19: Case Series and Review of the Literature. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17145062"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41398-021-01629-8","article-title":"Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions","volume":"11","author":"Han","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"577436","DOI":"10.1016\/j.jneuroim.2020.577436","article-title":"SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation","volume":"350","author":"Keyhanian","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_30","unstructured":"World Health Organization (WHO) (2022, May 03). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939752","article-title":"Hepatitis B virus-related cirrhosis: Natural history and treatment","volume":"26","author":"Chu","year":"2006","journal-title":"Semin. Liver Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cmi.2015.11.025","article-title":"Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C","volume":"22","author":"Sagnelli","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1590-8658(10)60686-X","article-title":"Natural history of chronic HBV infection: Special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis","volume":"43","author":"Villa","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1017\/S0950268819002012","article-title":"Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy","volume":"148","author":"Sagnelli","year":"2020","journal-title":"Epidemiol. Infect."},{"key":"ref_37","first-page":"1691","article-title":"An update on the treatment options for HBV\/HCV coinfection","volume":"18","author":"Sagnelli","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(70)90926-8","article-title":"Virus-like particles in serum of patients with Australia-antigen-associated hepatitis","volume":"1","author":"Dane","year":"1970","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2006.04.025","article-title":"Native hepatitis B virions and capsids visualized by electron cryomicroscopy","volume":"22","author":"Dryden","year":"2006","journal-title":"Mol. Cell."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3748\/wjg.v13.i1.14","article-title":"Hepatitis B virus taxonomy and hepatitis B virus genotypes","volume":"13","author":"Schaefer","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","article-title":"Replication of the genome of a hepatitis Blike virus by reverse transcription of an RNA intermediate","volume":"29","author":"Summers","year":"1982","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1002\/j.1460-2075.1988.tb03315.x","article-title":"The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription","volume":"7","author":"Bartenschlager","year":"1988","journal-title":"EMBO J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17780","DOI":"10.1073\/pnas.0508913102","article-title":"Dynamics of hepatitis B virus clearance in chimpanzees","volume":"102","author":"Murray","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2006-939755","article-title":"Immunopathogenesis: Role of innate and adaptive immune responses","volume":"26","author":"Visvanathan","year":"2006","journal-title":"Semin. Liver Dis."},{"key":"ref_52","first-page":"825","article-title":"Chronic infections with HBV infection","volume":"284","author":"Rehermann","year":"1999","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2003.08.012","article-title":"Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control","volume":"60","author":"Bertoletti","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.4049\/jimmunol.145.10.3442","article-title":"Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection","volume":"145","author":"Ferrari","year":"1990","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/135965350801300218","article-title":"A systematic review of T-cell epitopes in hepatitis B virus: Identification, genotypic variation and relevance to antiviral therapeutics","volume":"13","author":"Desmond","year":"2008","journal-title":"Antivir. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","article-title":"The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection","volume":"191","author":"Maini","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4+ T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1172\/JCI119308","article-title":"Cytotoxic T cells and viral hepatitis","volume":"99","author":"Chisari","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/ng0997-11","article-title":"Heterozygote advantage for HLA class-II type in hepatitis B virus infection","volume":"17","author":"Thursz","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gutjnl-2018-316644","article-title":"Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stageof infection","volume":"68","author":"Hoogeveen","year":"2019","journal-title":"Gut"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J. Infect Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.tim.2016.05.006","article-title":"Control and Eradication Strategies of Hepatitis B Virus","volume":"24","author":"Shih","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2005.03.009","article-title":"Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy","volume":"128","author":"Sung","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Bowden","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e35810","DOI":"10.5812\/hepatmon.35810","article-title":"Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review","volume":"16","author":"Tavakolpour","year":"2016","journal-title":"Hepat. Mon."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.3748\/wjg.v25.i26.3299","article-title":"Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention","volume":"25","author":"Sagnelli","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.12998\/wjcc.v9.i21.5769","article-title":"Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy","volume":"9","author":"Shih","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E11369","DOI":"10.1073\/pnas.1809028115","article-title":"Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure","volume":"115","author":"Chen","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","unstructured":"American Cancer Society (2022, May 03). Welcome to the COVID-19 and Cancer ECHO Series. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","article-title":"Hepatitis B virus screening for patients with cancer before therapy: American Society of clinical oncology provisional clinical opinion update","volume":"33","author":"Hwang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL) (2017). EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_77","first-page":"480","article-title":"Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: A systematic review","volume":"31","author":"Cholongitas","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"30642","DOI":"10.18632\/oncotarget.8907","article-title":"Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Tsai, Y.F., Hsu, C.M., and Hsiao, H.H. (2021). Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040267"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Affiliations expand Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12185-009-0359-5","article-title":"Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma","volume":"90","author":"Kusumoto","year":"2009","journal-title":"Int. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2008-10-163493","article-title":"How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation","volume":"113","author":"Liang","year":"2009","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Shih, C.A., Chen, W.C., Yu, H.C., Cheng, J.S., Lai, K.H., Hsu, J.T., Chen, H.C., and Hsu, P.I. (2015). Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132426"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"104765","DOI":"10.1016\/j.antiviral.2020.104765","article-title":"Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients","volume":"177","author":"Wu","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/jmv.23694","article-title":"Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma","volume":"85","author":"Matsui","year":"2013","journal-title":"J. Med. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0609.2010.01474.x","article-title":"Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative\/ HBcAb-positive: A multicenter retrospective study","volume":"85","author":"Ji","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e205619","DOI":"10.1001\/jamanetworkopen.2020.5619","article-title":"Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China","volume":"3","author":"Xie","year":"2020","journal-title":"JAMA Netw. Open."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/GO.20.00097","article-title":"COVID-19 and Cancer: Lessons from a Pooled Meta-Analysis","volume":"6","author":"Desai","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"ref_94","first-page":"19","article-title":"Report of cancer epidemiology in China, 2015","volume":"41","author":"Zheng","year":"2019","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting haracteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System","volume":"10","author":"Mehta","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/jmv.26404","article-title":"The outcome of COVID-19 in patients with hematological malignancy","volume":"93","author":"Yigenoglu","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/bjh.16852","article-title":"Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients","volume":"190","author":"Aries","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_100","first-page":"e16","article-title":"Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies","volume":"190","author":"Marquet","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/jmv.25972","article-title":"Clinical characteristics and outcomes of cancer patients with COVID-19","volume":"92","author":"Yang","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"010367","DOI":"10.7189\/jogh.10.010367","article-title":"Treatment delays in oncology patients during COVID-19 pandemic: A perspective","volume":"10","author":"Kumar","year":"2020","journal-title":"J. Glob. Health"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2020.04.018","article-title":"The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer","volume":"37","author":"Rubinstein","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e2017271","DOI":"10.1001\/jamanetworkopen.2020.17271","article-title":"Prevalence of Health Care Worker Burnout During the Coronavirus Disease 2019 (COVID-19) Pandemic in Japan","volume":"3","author":"Matsuo","year":"2020","journal-title":"JAMA Netw. Open."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s43018-020-0074-y","article-title":"The impact of the COVID-19 pandemic on cancer care","volume":"1","author":"Richards","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1200\/OP.20.00995","article-title":"Remote Home Monitoring of Patients With Cancer During the COVID Pandemic: A Pilot Study","volume":"17","author":"Steimer","year":"2021","journal-title":"JCO Oncol. Pr."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-020-05644-z","article-title":"Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium","volume":"181","author":"Dietz","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.urolonc.2020.05.017","article-title":"Urologic oncology surgery during COVID-19: A rapid review of current triage guidance documents","volume":"38","author":"Shinder","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref_110","unstructured":"ESMO\u2014European Society for Medical Oncology (2022, May 03). Guidelines|ESMO\u2014European Society for Medical Oncology. Available online: https:\/\/www.esmo.org\/guidelines\/cancer-patientmanagement-during-the-COVID-19-pandemic."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Monaghesh, E., and Hajizadeh, A. (2020). The role of telehealth during COVID-19 outbreak: A systematic review based on current evidence. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-09301-4"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1056\/NEJMp2005492","article-title":"Facing COVID-19 in Italy\u2014Ethics, Logistics, and Therapeutics on the Epidemic\u2019s Front Line","volume":"382","author":"Rosenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_113","first-page":"n2244","article-title":"Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination: National prospective cohort study","volume":"374","author":"Coupland","year":"2021","journal-title":"BMJ"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.01.033","article-title":"2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy","volume":"147","author":"Giesen","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.15585\/mmwr.mm7044e3","article-title":"Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults\u2014Nine states, January-September 2021","volume":"70","author":"Embi","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2021.5771","article-title":"Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: A US nationwide Veterans Affairs study","volume":"8","author":"Wu","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00520-021-06419-y","article-title":"Understanding COVID-19 vaccine hesitancy and resistance: Another challenge in cancer patients","volume":"30","author":"Mejri","year":"2022","journal-title":"Support Care Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.vaccine.2014.01.081","article-title":"Understanding vaccine hesitation about vaccines and vaccination from a global perspective: A systematic review of published literature, 2007\u20132012","volume":"32","author":"Larson","year":"2014","journal-title":"Vaccine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"SAGE Working Group on Vaccine Hesitancy Vaccine Hesitancy hesitancy: Definition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Lang, R., Benham, J.L., Atabati, O., Hollis, A., Tombe, T., Shaffer, B., Burns, K.K., MacKean, G., L\u00e9veill\u00e9, T., and McCormack, B. (2021). Attitudes, behaviours and barriers to public health measures for COVID-19: A survey to inform public health messaging. BMC Public Health, 21.","DOI":"10.1186\/s12889-021-10790-0"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e30424","DOI":"10.2196\/30424","article-title":"COVID-19 Vaccine\u2013Related Attitudes and Beliefs in Canada: National Cross-sectional Survey and Cluster Analysis","volume":"7","author":"Benham","year":"2021","journal-title":"JMIR Public Health Surveill."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Benham, J.L., Lang, R., Kovacs Burns, K., MacKean, G., L\u00e9veill\u00e9, T., McCormack, B., Sheikh, H., Fullerton, M.M., Tang, T., and Boucher, J. (2021). Attitudes, current behaviours and barriers to public health measures that reduce COVID-19 transmission: A qualitative study to inform public health messaging. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0246941"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.12998\/wjcc.v9.i19.5266","article-title":"COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report","volume":"9","author":"Wu","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_124","first-page":"e8645","article-title":"COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates","volume":"12","author":"Aldhaleei","year":"2020","journal-title":"Cureus"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jvh.13410","article-title":"Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy","volume":"28","author":"Miralpeix","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"706482","DOI":"10.3389\/fmed.2021.706482","article-title":"Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era","volume":"8","author":"Campbell","year":"2021","journal-title":"Front. Med."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/5\/567\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:04Z","timestamp":1760137744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/5\/567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":126,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["pathogens11050567"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11050567","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}